Aspirin’s Targeted Role in Preventing Heart Valve Disease for High-Risk Patients
A new analysis from the Multi-Ethnic Study of Atherosclerosis suggests that regular aspirin use may specifically reduce the risk of developing aortic valve calcification and severe aortic stenosis in individuals with high levels of lipoprotein(a) [Lp(a)], a known causal risk factor. The study, which followed nearly 6,600 participants, found that among those with elevated Lp(a), regular aspirin use (≥3 days/week) was associated with a significantly lower risk of both conditions, with hazard ratios as low as 0.17 for calcification and 0.02 for stenosis. In contrast, no such protective association was found for individuals with elevated LDL cholesterol, highlighting a potentially distinct mechanism and a precision-medicine approach to preventive cardiology.
Why it might matter to you:
This research points to a stratified preventive strategy where a common, low-cost medication like aspirin could be targeted based on a specific biomarker (Lp(a)) to mitigate cardiovascular complications. For clinicians managing patients with diabetes, who are at heightened risk for cardiovascular disease, understanding these nuanced associations is critical for refining risk assessment and personalizing preventive therapy beyond traditional lipid targets. It underscores the importance of considering broader cardiovascular pathophysiology, including valvular disease, within comprehensive diabetes care protocols.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
